Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3514889 | 0.86 | ALOX15 (0.42) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL3603087 | 0.81 | ALOX15 (0.39) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL10772553 | 0.80 | ALOX15 (0.44) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| Bicarbonate SCHEMBL9192764 | 0.78 | ALOX15 (0.48) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL261594 | 0.77 | — | — | |
| SCHEMBL6085112 | 0.77 | HDAC3 (0.40) | KMT2ASMN1; SMN2 | |
| SCHEMBL6135863 | 0.75 | ALOX15 (0.35) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL9772166 | 0.74 | ALOX15 (0.40) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL9772165 | 0.74 | ALOX15 (0.40) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL8411403 | 0.74 | MEN1 (0.43) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104262267-A | Modulators Of The Prostacyclin (pgi2) Receptor Useful For The Treatment Of Disorders Related Thereto | ARENA PHARM INC | 2015-01-07 | — | — | CN | claimed |
| US-6660858-B2 | Made by reacting a benzoxazole with a leaving group at the 2 position and a diamine of given formula | LION BIOSCIENCE AG (DE) | 2003-12-09 | — | — | US | claimed |
| US-20020161028-A1 | 2-aminobenzoxazole derivatives and combinatorial libraries thereof | LION BIOSCIENCE, AG (DE) | 2002-10-31 | — | — | US | claimed |
| WO-2002079753-A2 | 2-AMINOBENZOXAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2002-10-10 | — | — | WO | claimed |
| CN-104262267-A | Modulators Of The Prostacyclin (pgi2) Receptor Useful For The Treatment Of Disorders Related Thereto | ARENA PHARM INC | 2015-01-07 | — | — | CN | disclosed |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | disclosed |
| WO-2009093009-A1 | FUSED TRICYCLIC THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093013-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
| EP-2054417-A2 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB Pharma S.A. (BE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008020206-A2 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | WO | disclosed |
| US-6660858-B2 | Made by reacting a benzoxazole with a leaving group at the 2 position and a diamine of given formula | LION BIOSCIENCE AG (DE) | 2003-12-09 | — | — | US | disclosed |
| US-20020161028-A1 | 2-aminobenzoxazole derivatives and combinatorial libraries thereof | LION BIOSCIENCE, AG (DE) | 2002-10-31 | — | — | US | disclosed |
| WO-2002079753-A2 | 2-AMINOBENZOXAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2002-10-10 | — | — | WO | disclosed |
| EP-0228192-A2 | Renin-inhibitory oligopeptides, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1987-07-08 | — | — | EP | disclosed |
| EP-0074787-B1 | RENALLY ACTIVE DIPEPTIDES | SMITHKLINE BECKMAN CORPORATION (US) | 1985-03-27 | — | — | EP | disclosed |
| US-4448972-A | Adamantyl containing intermediates | SMITHKLINE BECKMAN CORPORATION (US) | 1984-05-15 | — | — | US | disclosed |
| US-4395401-A | Renally active dipeptides | SMITHKLINE BECKMAN CORPORATION (US) | 1983-07-26 | — | — | US | disclosed |
| US-4387049-A | Adamantyl containing peptides | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-07 | — | — | US | disclosed |
| EP-0074787-A1 | Renally active dipeptides | SMITHKLINE BECKMAN CORPORATION (US) | 1983-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161028-A1 | 2-aminobenzoxazole derivatives and combinatorial libraries thereof | BCAT2, IL4I1, BCAT1 | ALOX15 3738/4885MEN1 2998/4885CYP1A2 351/4885 |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | MAPK15, MOK, MAPK14 | ALOX15 728/4885MEN1 1220/4885CYP1A2 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.